EN DE
Watch Lifecore Biomedical Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lifecore Biomedical Inc. (LFCR) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Lifecore Biomedical Inc. stock $6.32, price $6.42, that is 1.5% below the price, quality 31 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

LB Lifecore Biomedical Inc. logo Thin data Nov 13, 2026

Lifecore Biomedical Inc.

LFCR · US

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Generates free cash flow 
Fair value $6.32 · Fairly valued 
Mixed Growth (revenue 5y +5.1 %/yr in USD) 
Negative equity (buybacks among others) 
Revenue last quarter 19% below a year ago. 
Quality 31/100 
Falling price (downtrend) 
Loss-making · -66.8% net margin (TTM) 
Trails peers (2/10) 
Narrow moat 10/100
Thin data 
Estimate
Watch Lifecore Biomedical Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$11.93 $1.67 Fair Value $6.32 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range $1.67 – $11.93 · fair‑value band $4.74 – $7.90 · the $6.42 price screens above the $6.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.

Follow Lifecore Biomedical in your weekly email

Every Wednesday you see whether Lifecore Biomedical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally.

Show moreShow less

It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.

The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications.

In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies.

The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Stock analysis

Lifecore Biomedical Inc. (LFCR) currently trades at $6.42, while our estimate is $6.32, so the stock looks roughly fairly valued today (gap 1.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $4.74 (bear) to $7.90 (bull), the price of $6.42 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Lifecore Biomedical Inc. reported revenue of $129M in FY2026 versus $186M in FY2022, a compound −8.6%/yr. Reported net income was −$30.8M in FY2026.

Key figures

Market cap $241M Micro · P/S ratio 2.27 · EPS (TTM) $−1.27 · Net margin −23.8% · Return on equity −76.4% · Return on assets (EBIT) −3.3% (5-year average) · Operating margin −3.5% · Revenue (TTM) $106M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (medium confidence).

What moves the price

The share trades about 27% below its 52-week high and 75% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −2%, LFCR screens cheaper than that median.

Fair Value

Bear $4.74 Fair Value $6.32 Bull $7.90
Price $6.42 · Downside -1.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 17
How much profit the company makes from its sales and capital
Quality Growth 62
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 8
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 32
How calm the share price moves, does not count
Price momentum 69
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 33
Distance to the 52-week high, does not count
New shares 1
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Start year 2021 (pandemic). Over 10 years: −13.3% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8.7% (2021) → −1.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+38.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +34.9% a year for the price and +8.8% for the forecasts.
Forecast 2027 (sales)+14.1%
Projected 2028 (sales)+12.8%
Projected 2029 (sales)+11.4%
Projected 2030 (sales)+10.1%
Projected 2031 (sales)+8.7%

Watch LFCR, get fair value alerts →

Compare Lifecore Biomedical Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −1.5% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −13.3% · Bottom 25%
Net margin (12 months) −66.8% · Bottom 25%
Operating margin (12 months) −3.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −18.6% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 2.26× · Cheaper than median
Price / free cash flow (fiscal year) 38.7× · Pricier than median
EV/EBITDA 86.2× · Priciest 25%
PEG 2.66× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)31 · sector 19
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs LFCR
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs LFCR
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs LFCR
Haleon plc HLN $9.20 $8.47 −8% vs LFCR
Merck KGaA MRK €149.70 €108.83 −27% vs LFCR
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs LFCR
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs LFCR
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs LFCR
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs LFCR
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs LFCR

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lifecore Biomedical Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Lifecore Biomedical Inc. Fair Value". https://www.fairvalue-calculator.com/stock/LFCR

Frequently asked questions

Is Lifecore Biomedical Inc. (LFCR) overvalued or undervalued?
As of Nov 13, 2026, our estimate of fair value is $6.32 versus a price of $6.42, about 2% lower (fairly valued).
What is the fair value of LFCR?
Our estimate for Lifecore Biomedical Inc. is $6.32 (as of Nov 13, 2026), built from audited fundamentals. The current price: $6.42.
What is the quality score of LFCR?
Lifecore Biomedical Inc. has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lifecore Biomedical Inc. (LFCR)?
Our calculated price target is the estimate of $6.32 (as of Nov 13, 2026). Cautious scenario $4.74, optimistic scenario $7.90. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Lifecore Biomedical Inc. stock forecast for 2026?
Our estimate puts fair value at $6.32, about 2% lower versus a price of $6.42 (fairly valued). Cautious scenario $4.74, optimistic scenario $7.90. The calculation is refreshed regularly with new filings.
What is the revenue of Lifecore Biomedical Inc. (LFCR)?
Lifecore Biomedical Inc. reported trailing-twelve-month revenue of about $106M (latest available figure, as of Nov 13, 2026).
What growth is priced into Lifecore Biomedical Inc. (LFCR)?
For today's price to be fair in a discounted-cash-flow model, Lifecore Biomedical Inc. would have to grow free cash flow by 38.2 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 5.1 % per year. As of Nov 13, 2026.
What discount rate (WACC) does the fair value of LFCR use?
Our models discount Lifecore Biomedical Inc. at 12.6 %: a base by market capitalisation (micro), damped by beta 0.97, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Lifecore Biomedical Inc. that is +38.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has Lifecore Biomedical Inc. (LFCR) delivered so far?
Over the past 5 years revenue at Lifecore Biomedical Inc. grew 5.1 % a year. The price currently implies free-cash-flow growth of +38.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Lifecore Biomedical Inc. (LFCR) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Lifecore Biomedical Inc. (+38.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Lifecore Biomedical Inc. (LFCR)?
The free-cash-flow yield on the price is 2.58 %: that much free cash flow Lifecore Biomedical Inc. produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Lifecore Biomedical Inc. (LFCR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lifecore Biomedical Inc. it is $6.32 per share (as of Nov 13, 2026), against a price of $6.42.
Is Lifecore Biomedical Inc. stock overvalued or undervalued in 2026?
As of Nov 13, 2026, LFCR trades above its calculated fair value: price $6.42, fair value $6.32, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LFCR?
No. The price is what the market pays today ($6.42); the fair value is what the company's own numbers justify ($6.32). For Lifecore Biomedical Inc. the two are $0.0950 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lifecore Biomedical Inc. worth?
The market values Lifecore Biomedical Inc. at about $241M (market capitalisation, as of Nov 13, 2026). Per share that is $6.42; our models calculate a fair value of $6.32 per share.
What do the bullish and bearish scenarios say about LFCR?
Our models span a range for Lifecore Biomedical Inc.: cautious scenario $4.74, base $6.32, optimistic $7.90 per share (as of Nov 13, 2026, price $6.42). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of LFCR?
The PEG ratio of Lifecore Biomedical Inc. is 2.66 (P/E divided by earnings growth, as of Nov 13, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Lifecore Biomedical Inc. (LFCR)?
Balance-sheet figures for Lifecore Biomedical Inc. (as of Nov 13, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is LFCR from its 52-week high?
Lifecore Biomedical Inc. trades at $6.42, about 27% below its 52-week high of $8.82 and 75% above the low of $3.66 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $6.32 is for.
Which stocks are comparable to Lifecore Biomedical Inc.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lifecore Biomedical Inc. stock attractive at the current price?
The data as of Nov 13, 2026: price $6.42, calculated fair value $6.32 (−2%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Lifecore Biomedical Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lifecore Biomedical Inc. (LFCR)?
The closing price on Nov 16, 2026 was $6.42. Our estimate is $6.32, about 2% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lifecore Biomedical Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Lifecore Biomedical Inc.

How large is the market capitalisation of Lifecore Biomedical Inc. (LFCR)?
The market capitalisation of Lifecore Biomedical Inc. is $241M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lifecore Biomedical Inc. (LFCR)?
The price-to-sales ratio of Lifecore Biomedical Inc. is 2.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lifecore Biomedical Inc. (LFCR)?
Earnings per share at Lifecore Biomedical Inc. are $−1.27. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lifecore Biomedical Inc. (LFCR)?
The net margin of Lifecore Biomedical Inc. is −23.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lifecore Biomedical Inc. (LFCR)?
The return on equity (ROE) of Lifecore Biomedical Inc. is −76.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lifecore Biomedical Inc. (LFCR)?
On an EBIT basis the return on assets of Lifecore Biomedical Inc. is −3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lifecore Biomedical Inc. (LFCR)?
The operating margin of Lifecore Biomedical Inc. is −3.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lifecore Biomedical Inc. (LFCR)?
Revenue at Lifecore Biomedical Inc. is down 18.6% versus a year earlier (3y avg +5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Lifecore Biomedical Inc. (LFCR) carry?
The net debt of Lifecore Biomedical Inc. is $125M (fiscal year 2026, ≈ 20.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Lifecore Biomedical Inc. in the live analysis

One click puts Lifecore Biomedical Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.